What is GBM AGILE?
GBM AGILE is the world's first adaptive clinical trial platform with a unique approach to the traditional clinical trial which will enable faster and cost-effective development of new treatments versus conventional trials.
GBM AGILE tests multiple drugs on a greater number of patients in a highly compressed timeframe and for a fraction of the cost of a traditional clinical trial.
Traditional Clinical Trial
It takes several years to evaluate a single drug.
Not experimental. Dependent on results from a single drug used on multiple patients at one time.
Expensive treatment pathway with slow progress.
Doesn’t allow cross-learning and the opportunity for learning to improve treatment outcomes.
The traditional research pathway involves changing one variable at a time and testing one treatment on multiple participants.
Expensive process with an experimental drug taking almost 12 years to be available in the market.
GBM AGILE has a primary objective of improving the overall survival in patients with newly diagnosed or recurrent GBM.
GBM AGILE Trial
The platform is adaptive, allowing multiple drugs and drug combinations from different pharmaceutical companies to be evaluated simultaneously.
Innovative to add experimental therapies as new information about promising new drugs are identified and remove therapies as they complete their evaluation.
A more efficient and cost-effective mechanism for accelerating treatments to patients.
The global platform allows patient tumour prototypes to be treated with similar drugs, increasing efficacy and survival.
Credible learning environment built by a group of more than 130 clinicians, researchers, leaders from government, industry and patient advocates globally.
An efficient approach to drug development, improving treatment accessibility and one that has received significant interest and support from clinicians, industry, and regulatory agencies worldwide.
vs
The Global Coalition for Adaptive Research (GCAR) is the sponsor of GBM AGILE trials. Partnering with Cure Brain Cancer Foundation, the goal of these trials is to drive progress for patients faster.
GCAR unites physicians, clinical researchers, advocacy and philanthropic organizations, biotech/pharma, health authorities, and other key stakeholders in healthcare to expedite the discovery and development of treatments for patients with rare and deadly diseases.
Questions?
How GBM AGILE
Expanded into Australia ...
2019
The GBM trial, sponsored by the Global Coalition for Adaptive Research (GCAR) opens in the United States.
The trial continued to expand globally. More than 45 GBM AGILE trial sites are established around the world, improving treatment accessibility for brain cancer patients internationally.
2013
Cure Brain Cancer Foundation invests in bringing the revolutionary GBM AGILE clinical trial to Australia.
To date, the foundation has invested more than $30 million and is the largest dedicated funder for brain cancer research in Australia.
More Patients Helped
The trial continues to grow in helping more patients get access to these groundbreaking treatments.
Currently the GBM AGILE trial has screened more than 1,300 patients with enrollment rates being three to four times greater than traditional GBM trials.